tbuckley/cabot-search huggingface dataset:
Abstract 1769: Caveolin-1 Regulates TGF-Beta Signaling in Cardiac Remodeling
Authors: Shelley Miyasato, Oana Bollt, Joyce Pike, Ann Hashimoto, Ralph V Shohet, Claude Jourdan Le Saux
Journal: Circulation (2008)

In cardiac fibrosis, fibrous tissue replaces healthy contractile tissue. The regulation of these processes is controlled in large part by transforming growth factor-β (TGF-β). Caveolin-1 (cav1) regulates TGF-β signaling by either sequestering the TGF-β receptor complex or enhancing its degradation. Thus, cav1 may prevent TGF-β directed fibrosis. To investigate the role of cav1 in cardiac remodeling, we performed left ventricular cryoinjury in Cav1-deficient (Cav1−/−) mice and wild-type controls. Ventricular function was followed by echocardiography, and 3, 14, and 30 days after surgery, cardiac RNA and protein were analyzed for inflammatory responses, connective tissue and TGF-β signaling related proteins. Cryoinjured WT presented reduced cav1 expression. Concurrently, evidence of activation of TGF-β signaling was measured as shown by increase of Smad2 phosphorylation. Moreover Cav1−/− cryoinjured hearts had enhanced Smad2 phosphorylation. Collagen gene expression was transiently upregulated in cryoinjured WT mice 3 days post surgery (2.5-fold) and this elevation persisted in Cav1−/− hearts (3.5-fold at 14 days). The level of collagenases (mmp-8 and -13) expression was dramatically increased in the 3-day cryoinjured WT but not in Cav1−/− mice. As a result, augmented collagen deposition, resulting from increased collagen expression and reduced degradation by collagenases, was observed by Masson’s trichrome and picrosirius staining in injured Cav1−/− hearts. WT mice had a transient decline in fractional shortening (FS) but function returned to baseline by 30 days post-injury. In contrast, cryoinjured Cav1−/− mice had a significant lower % FS after 30 days compared to baseline or to cryoinjured WT (67.4 ± 9.6, 76 ± 11, 76.9 ± 5.5, respectively). Moreover Cav1−/− mice presented an altered inflammatory response following cryoinjury. Reduced macrophage infiltrates and IL-6 level of expression were also measured in cryoinjured Cav1−/− mice. These data indicate that in absence of caveolae, TGF-β signaling is enhanced, and this leads to a disordered inflammatory response and suboptimal cardiac remodeling that may impair left ventricular function.
Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose
Authors: Wolfgang Römer, Axel-R. Hanauske, Sibylle Ziegler, Ralf Thödtmann, Wolfgang Weber, Christoph Fuchs, Wolfgang Enne, Michael Herz, Christoph Nerl, Manfred Garbrecht, Markus Schwaiger
Journal: Blood (1998)
Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study)
Authors: John Porter, Patrick B Walter, Lynne D Neumayr, Patricia Evans, Marcela G Weyhmiller, Paul Harmatz, John C. Wood, Jeffery L Miller, Guenter Weiss, Quing Yuan, Zhiyue J Wang, Regine Grosse, Bjoern P Schoennagel, Joerg Meerpohl, Roland Fischer, Peter Nielsen, Markus Seifert, Elliott Vichinsky
Journal: Blood (2013)
Long-term maintenance of prognostic value of survivin protein expression in T4 breast cancer patients: 10-year results from a single institution
Authors: B. Massidda, M. Ionta, V. Pusceddu, M. Murgia, B. Frau, M. Perra, C. Maxia, D. Murtas, L. Minerba, P. Sirigu
Journal: Journal of Clinical Oncology (2008)

22124 Background: Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in many tumors, including breast cancer and is considered a promising molecular target for emerging therapies. Survivin's overexpression is associated with poor clinical prognosis and chemo- resistance in some tumors. Survivin seems to be a strong predictor of poor survival in early-stage breast cancer patients (pts),nevertheless its role in predicting prognosis in Locally Advanced Breast Cancer (LABC) pts is still unknown. Aim of the present study was to investigate the prognostic relevance of survivin on terms of survival in LABC T4 breast cancer. Methods: Survival was estimated by Kaplan-Meier method and differences between groups were tested by log-rank test. Survivin protein was measured in primary tumor, by IHC method (samples with more than 10% of cells stained were considered to be positive); 53 out of 126 consecutive LABC T4 breast cancer pts observed between 1991 and 2001, were evaluable. Survivin protein was positive in 21 (40%), negative in 32 (60%) cases; median age was 51 years (32–67), clinical T4abc 38 pts (72%), T4d 15 pts (28%); N+ 50 pts (94%); ERneg 25 pts (47%), PRneg 36 pts (68%); HER2 status by IHC was neg in 43 pts (81%), pos in 10 pts (19%). All pts received anthracycline-based primary chemotherapy, surgery, radiation, adjuvant chemotherapy and Hormone when indicated. Results: At a median follow up of 125 months (70–182), 10y DFS and OS were 32,1% and 43,4% for the entire population, respectively. Patients with low survivin expression showed significantly better OS and a trend of improving DFS than patients with high survivin expression. Conclusions: Our data show that the overexpression of survivin protein is a negative prognostic factor in LABC pts, maintening its relevance even at long term. Survivin protein should be considered a new marker for treatment decision making and a promising target for innovative therapies. Overall (53) 5 y-10 y Survivin neg (32) 5 y-10 y Survivin pos (21) 5 y-10 y p value DFS 45% 32,1% 59,4% 37,5% 23,8% 23,8% 0.095 OS 60,4% 43,4% 75% 56,3% 38% 23,8% 0.009 No significant financial relationships to disclose.
Abstract 9371: Diuretic Use and the Benefit of Cardiac Resynchronization Therapy to Prevent Heart Failure and Death: Secondary Analysis of Data from MADIT-CRT.
Authors: Robert E Goldstein, Mark C Haigney, Ronald J Krone, Scott A McNitt, Arthur J Moss
Journal: Circulation (2011)

MADIT-CRT demonstrated a reduction in the composite endpoint of heart failure (HF) or death with CRT-D vs. ICD-only therapy in patients with NYHA class I-II, ejection fraction &lt;0.30, and QRS &gt;130ms. Additional predictive variables would aid in selecting patients for preventive CRT-D. We hypothesized that diuretic use at study enrollment might identify patients with more advanced cardiac impairment and incipient HF and thus greater potential for reduction in later overt HF or death with CRT-D. At baseline, 1228 patients were diuretic users and 592 were diuretic non-users. Kaplan-Meier graphs are shown for the two subgroups. Diuretic users showed a relatively high probability of overt HF or death with ICD alone plus a large, highly significant reduction in the risk of this end point with CRT-D therapy. Nonusers had fewer of these events with ICD and modest reduction of borderline statistical significance with CRT-D. As anticipated, the predictive information derived from diuretic use was not unique: when adjusted for imbalances in relevant baseline characteristics (e.g., serum creatinine), diuretic users and non-users experienced similar benefit from CRT-D therapy. Conclusion: in MADIT-CRT, the physician's pre-enrollment decision to use diuretics discriminated between a subgroup achieving a strikingly significant benefit from CRT-D therapy and one receiving little likelihood of benefit. This finding may aid in selecting optimal management for patients resembling MADIT-CRT enrollees.
Abstract 14956: Use of Late Gadolinium Enhancement to Differentiate Cardiac Sarcoidosis with Ventricular Dysfunction from End-stage phase of Hypertrophic Cardiomyopathy and dilated cardiomyopahty
Authors: Emi Tateishi, Teruo Noguchi, Yoichi Goto, Naoaki Yamada
Journal: Circulation (2011)

Background: Patients with cardiac sarcoidosis (CS) are often initially misdiagnosed with idiopathic dilated cardiomyopathy (DCM) or end-stage phase of hypertrophic cardiomyopathy (Es-HCM) due to th...
Quantitative Evaluation of the Penile Vascular Status by Means of the 99mTc-Penogram in Conjunction with either Papaverine or Prostaglandin Ei in the Anaesthetised Baboon Model
Authors: Irene C. Dormehl, D. De Bruin, L. Jacobs, M. Maree, D.J. Du Plessis
Journal: European Urology (1991)
Abstract 2909: Diastolic Function is Abnormal in Subjects with Low Aortic Compliance.
Authors: Manish Jain, Susan Matulevicius, David Leonard, Ronald Peshock, Manisha Shah
Journal: Circulation (2007)

INTRODUCTION: Heart failure with normal ejection fraction (HFNEF) or diastolic heart failure is responsible for nearly 50% of all CHF admissions. Aortic compliance is noted to be reduced in patient...
Abstract 12734: Cooling Duration and Rewarming Speed in Therapeutic Hypothermia for Out-of-hospital Cardiac Arrests: How Should We Combine the Protocols?
Authors: Nobuaki Kokubu, Mamoru Hase, Kazufumi Tsuchihashi, Junichi Nishida, Naohiro Yonemoto, Hiroyuki Yokoyama, Ken Nagao, Tetsuji Miura, Hiroshi Nonogi
Journal: Circulation (2011)

Background: Therapeutic hypothermia (TH) improves outcomes of patients with out-of-hospital cardiac arrest (OHCA). However, how we should combine cooling protocol and rewarming protocol to maximize...
Abstract 4858: Patterns in Beta Blockerw use ith Cardiac Resynchronization Therapy: Insights from the COMPANION Study
Authors: Frank McGrew, John Boehmer, Alan Bank, Elizabeth Galle, Patrick Yong, Jill Leigh, Michael R Bristow
Journal: Circulation (2008)

Cardiac resynchronization therapy (CRT) is typically delivered in addition to background heart failure medications that include beta blockers (BB). Since CRT devices also provide rate support, it was hypothesized that CRT may influence BB use post-implant. We sought to compare BB use in the treatment arms of the COMPANION study, which randomized patients (pts) to optimal pharmacological therapy (OPT) alone or in combination with CRT with or without a defibrillator. The database was analyzed retrospectively for a 12-month period post-randomization. BB dosages were evaluated at the 12-month visit with the last follow-up (FU) visit used for those without 12 month FU data. Pts with no FU data were excluded. Dosages are expressed in carvedilol equivalents. The median dose between the two treatment arms were compared as well as up/down titration rates. Of 1520 pts randomized, 1376 (91%) were followed for at least three months and 689 (50%) were followed for at least 12 months. The median dose was 25 mg/day for both groups at baseline (p=0.93) and again at 12 months (p=0.53). BB use between arms is characterized in the tables below: In this retrospective analysis of the COMPANION trial, there was no significant association between treatment arm and BB drug use. Up/down-titration rates and median dosages were virtually identical between the two arms. COMPANION did not require investigators to increase BB dosage; accordingly, a prospective study would be needed to definitively determine if BB dosage can be titrated more aggressively with CRT.
Human Body
Authors: Harriet S. Meyer
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4727: Diastolic Untwisting Correlates Inversely with the End Systolic Area and Negative dP/dt in an Experimental Animal Model
Authors: Muhammad Ashraf, Aman Mahajan, Kalyanam Shivkumar, David J Sahn
Journal: Circulation (2008)

Untwisting of the left ventricle (LV) has been shown to be related to early diastolic filling. We studied rotational dynamics of the LV in open chest rabbits at different loading conditions. Five r...
Abstract 6097: Coronary Flow Reserve Exceeds Resting Myocardial Perfusion Abnormalities in Hibernating Myocardium: Implications for Using Resting Myocardial Contrast Echocardiography Versus Dobutamine Echocardiography for the Detection of Hibernating Myocardium
Authors: Michael Hickman, Leah Burden, Roxy Senior
Journal: Circulation (2008)
c-myb Transactivates the Human Cyclin A1 Promoter and Induces Cyclin A1 Gene Expression
Authors: Carsten Müller, Rong Yang, Gregory Idos, Nicola Tidow, Sven Diederichs, Olaf M. Koch, Walter Verbeek, Timothy P. Bender, H. Phillip Koeffler
Journal: Blood (1999)
Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.
Authors: C D Atkins
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.12.3916 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9850039 Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer. C D AtkinsxC D AtkinsSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.12.3916 First Page PDF © 1998 by American Society of Clinical Oncology
Total Cholesterol Content of Erythrocyte Membranes Is Increased in Patients With Acute Coronary Syndrome
Authors: Dimitrios N. Tziakas, Juan Carlos Kaski, Georgios K. Chalikias, Carlos Romero, Salim Fredericks, Ioannis K. Tentes, Alexandros X. Kortsaris, Dimitrios I. Hatseras, David W. Holt
Journal: Journal of the American College of Cardiology (2007)
Abstract 64: A Tale of Seven EMS Systems: An Impedance Threshold Device and Improved CPR Techniques Double Survival Rates After Out-of-Hospital Cardiac Arrest
Authors: Tom P Aufderheide, Marvin Birnbaum, Charles Lick, Brent Myers, Laurie Romig, Joseph Stothert, Levon Vartanian
Journal: Circulation (2007)

Introduction: Maximizing outcomes after cardiac arrest depends on optimizing a sequence of interventions from collapse to hospital discharge. The 2005 American Heart Association (AHA) Guidelines recommended many new interventions during CPR (‘New CPR’) including use of an Impedance Threshold Device (ITD). Hypothesis: The combination of the ITD and ‘New CPR’ will increase return of spontaneous circulation (ROSC) and hospital discharge (HD) rates in patients with an out-of-hospital cardiac arrest. Methods: Quality assurance data were pooled from 7 emergency medical services (EMS) systems (Anoka Co., MN; Harris Co., TX; Madison, WI; Milwaukee, WI; Omaha, NE; Pinellas Co., FL; and Wake Co., NC) where the ITD (ResQPOD®, Advanced Circulatory Systems; Minneapolis, MN) was deployed for &gt;3 months. Historical or concurrent control data were used for comparison. The EMS systems simultaneously implemented ‘New CPR’ including compression/ventilation strategies to provide more compressions/min and continuous compressions during Advanced Life Support. All sites stressed the importance of full chest wall recoil. The sites have a combined population of ~ 3.2 M. ROSC data were available from all sites; HD data were available as of June 2007 from 5 sites (MN, TX, Milwaukee, NE, NC). Results: A total of 893 patients treated with ‘New CPR’ + ITD were compared with 1424 control patients. The average age of both study populations was 64 years; 65% were male. Comparison of the ITD vs controls (all patients) for ROSC and HD [Odds ratios (OR), (95% confidence intervals), and Fisher’s Exact Test] were: 37.9% vs 33.8% [1.2, (1.02, 1.40), p=0.022] and 15.7% vs 7.9% [2.2, (1.53, 3.07), p&lt;0.001], respectively. Patients with ventricular fibrillation had the best outcomes in both groups. Neurological outcome data are pending. Therapeutic hypothermia was used in some patients (MN, NC) after ROSC. Conclusion: Adoption of the ITD + ‘New CPR’ resulted in only a &gt;10% increase in ROSC rates but a doubling of hospital discharge rates, from 7.9% to 15.7%, (p&lt;0.001). These data represent a currently optimized sequence of therapeutic interventions during the performance of CPR for patients in cardiac arrest and support the widespread use of the 2005 AHA CPR Guidelines including use of the ITD.
The Impact of Renin-Angiotensin-Aldosterone System Blockade on Heart Failure Outcomes and Mortality in Patients Identified to Have Aortic Regurgitation
Authors: Douglas H.J. Elder, Li Wei, Benjamin R. Szwejkowski, Renata Libianto, Adnan Nadir, Maheshwar Pauriah, Sushma Rekhraj, Tiong K. Lim, Jacob George, Alex Doney, Stuart D. Pringle, Anna-Maria Choy, Allan D. Struthers, Chim C. Lang
Journal: Journal of the American College of Cardiology (2011)
Abstract 17890: Cardiomyocyte-Specific ATGL Over-Expression Prevents Doxorubicin-Induced Cardiac Dysfunction in Female Mice
Authors: Jeevan Nagendran, Petra C Kienesberger, Thomas Pulinilkunnil, Jason R Dyck
Journal: Circulation (2011)

Anthracyclines such as, doxorubicin (DOX) are an effective class of antineoplastic agents. Despite its efficacy in the treatment of a variety of cancers including breast cancer, the clinical use of DOX is limited by cardiac side effects. While it has been shown that DOX alters myocardial fatty acid metabolism, it is poorly understood whether variations in myocardial triacylglycerol (TG) metabolism contribute to DOX-induced cardiotoxicity. Since TG catabolism in the heart is primarily controlled by adipose triglyceride lipase (ATGL), this study examined the influence of DOX on cardiac ATGL expression and TG levels as well as the consequence of forced-expression of ATGL in the setting of DOX-induced cardiotoxicity. To do this, wild type (WT) mice and mice with cardiomyocyte-specific ATGL over-expression (MHC-ATGL) received weekly intraperitoneal injections of saline or DOX (8mg/kg) for four weeks. Heart rate, heart weight to tibia length ratio and DOX-induced body weight loss were comparable between genotypes. As expected, myocardial TG content was significantly reduced in MHC-ATGL mice compared to the WT following DOX treatment. Echocardiographic analysis also revealed a significant reduction of systolic heart function (% ejection fraction) in DOX-treated WT mice (saline, 54.6 ± 3.6 vs. DOX, 47.1 ± 1.0, p&lt;0.05), an effect that was not observed in DOX-treated MHC-ATGL mice (saline, 58.7 ± 2.6 vs DOX, 57.2 ± 2.4, p = 0.7). The wet to dry lung weight ratio was increased in DOX-treated WT (saline, 10.1 ± 0.9 vs. DOX, 14.0 ± 1.0, p&lt;0.05), but not MHC- ATGL mice (saline, 9.6 ± 0.6 vs. DOX, 10.9 ± 0.2, p = 0.12), suggesting a protection from pulmonary signs of heart failure. Surprisingly, the preservation of cardiac function in MHC-ATGL mice following DOX treatment was associated with decreased protein expression of PPARα, Oxpat, CD36, and FATP1 as well as increased phosphorylation of acetyl CoA carboxylase when compared to DOX-treated WT mice, indicating a reduction of fatty acid uptake and subsequent oxidation in the cardiomyocyte. Taken together, our data suggest that chronic reduction in myocardial TG content by cardiomyocyte-specific ATGL over-expression is able to prevent DOX-induced cardiac dysfunction.
Abstract 3916: Effect of Eplerenone Versus Spironolactone on Adiponectin and Hemoglobin A1c Levels in Patients With Chronic Heart Failure
Authors: Takayoshi Tsutamoto, Keizo Nishiyama, Masayuki Yamaji, Chiho Kawahara, Masanori Fujii, Masaru Hayashi, Minorue Horie
Journal: Circulation (2009)

Background. Adiponectin has important metabolic effects including insulin sensitivity and plasma adiponectin level is elevated in patients with chronic heart failure (CHF). Hemoglobin A1c (HbA1c) level is reported to be an independent risk factor for mortality in CHRAM study population, suggesting the important role of insulin resistance in CHF.  Methods and Results. To compare the metabolic effect of a selective mineralocorticoid receptor blocker eplerenone with spironolactone in patients with CHF, 84 stable outpatients of CHF who received standard therapy such as ACE-I or ARB and b blockers, were randomized (1:2) to spironolactone (25mg/day) or eplerenone (50mg/day). We measured plasma levels of brain natriuretic peptide (BNP), adiponectin, HbA1c and cortisol were determined before and 4 months after either spironolactone or eplerenone. There was no difference in the baseline characteristics including hemodynamics and plasma levels of biomarkers between two groups. In both groups, plasma BNP levels were significantly decreased and plasma aldosterone levels were significantly increased after 4 months. In patients receiving spironolactone (n=29), plasma adiponectin was significantly decreased (14.5±9.1 vs. 11.8±8.4 ug/mL, p=0.0004) and HbA1c was significantly increased (5.6±0.6 vs. 5.9±0.7 %, p  Conclusion. These findings indicate that the metabolic effects of eplerenone are different from those of spironolactone and that a selective mineralocorticoid receptor blocker eplerenone is superior to spironolactone in metabolic effects in patients with CHF.